Lescol fluvastatin: Phase IV results; marketed to treat hypercholesterolemia, mixed dyslipidemia and atherosclerosis

Researchers published in JAMA previously reported results of a 4-year double-blind international

Read the full 127 word article

How to gain access

Continue reading with a
two-week free trial.